米索前列醇片在促待产妇宫颈成熟及引产中的应用  

Application of misoprostol tablets in parturients with cervical ripening and labor induction

作　　者：王凤双[1] 

机构地区：[1]黑龙江省佳木斯市妇幼保健院,黑龙江佳木斯154003

出　　处：《中国民康医学》2015年第2期47-48,共2页Medical Journal of Chinese People’s Health

摘　　要：目的:探索米索前列醇片在促待产妇宫颈成熟与引产的合适用法、用量。方法:选取待产妇168例,随机分成两组,A组待产妇舌下含服100μg米索前列醇片;B组待产妇阴道后穹隆置药50μg。收集两组待产妇用药后的宫颈成熟度、待产时间、产程以及新生儿安全指标等数据,进行统计学分析。结果:舌下含服和阴道给药在促待产妇宫颈成熟、有效率、待产时间、产程等作用上没有明显差别,但舌下含服组待产妇的剖宫产及新生儿窒息比率较低。结论:舌下含服100μg和阴道给药50μg米索前列醇片在有效性上效果相当,但舌下含服组的安全性更高。Objective：To explore the appropriate use and dosage of misoprostol tablets in parturients with cervical ripening and labor induction. Methods：168 parturients were chosen and divided into two groups randomly. Group A parturients was given 100μg misoprostol tablets by sublingual administration, while 50μg misoprostol was placed in vaginal vault in group B parturients. The data of cervical maturity, expectant time, labor time and neonatal safety of the two groups parturients were collected for statistical analysis. Results：There were no differences in the cervical maturity, effective rate, expectant time and labor time between the two groups partu-rients, but the cesarean section and neonatal asphyxia rates were lower in the Group A parturients. Conclusions：The efficacies of both sublingual and vaginally groups are equivalent, but sublingual group is safer.

关 键 词：米索前列醇片 宫颈成熟 引产 

分 类 号：R719.3[医药卫生—妇产科学]